In this paper we report the results of testing the therapeutic effects of radioimmunotherapy with 225Ac-T delivered through the intraductal route in a HER-2 positive human DCIS xenograft model in immunodeficient female NSG mice. Here, ERBB2 is linked to ductal breast carcinoma in situ.